Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 1021

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 3
Chunk 1021
---
 generated total gross proceeds of $9,000,000.

Simultaneously with the
consummation of the Initial Public Offering and the sale of the Units, the Company consummated the private placement (the “Private
Placement”) of 430,000 Units (the “Private Placement Units”), to Bellevue Global Life Sciences Investors LLC
(the “Sponsor”) at a price of $10.00 per Placement Unit, for an aggregate purchase price of $4,300,000. Each Unit and
Private Placement Unit consists of one share of common stock, par value $0.0001 (the “Common Stock”), a warrant
to purchase one share of Common Stock (the “Public Warrants” and “Private Placement Warrants” and collectively,
the “Warrants”) and one right which entitles the holder thereof to receive one-tenth (1/10) of
a share of common stock (the “Public Rights” and Private Placement Rights” and collectively, the “Rights”),
as described in Notes 3 and 4.

The Company’s management has
broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale
of Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a
Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company
must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held
in the Trust Account (as defined below) (excluding the amount of deferred underwriting fees and taxes payable on income earned on the
Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete
a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of
the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment
company under the Investment Company Act of 1940, as amended (the “Investment Company Act”).

F-7

OSR HOLDINGS, INC.

(f/k/a Bellevue Life Sciences Acquisition Corp.) 

NOTES TO
CONSOLIDATED FINANCIAL STATEMENTS

DECEMBER 31, 2024

Upon closing of the
Initial Public Offering